SCHEMBL1736743

SCHEMBL1736743

COC(=O)C1CN(S(=O)(=O)C(C)C)C(=O)N1c1ccccc1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 3/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MMP2 P08253 4/20 0.37
ANPEP P15144 1/20 0.37
CTSS P25774 1/20 0.35
ATM Q13315 1/20 0.35
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
NOTUM Q6P988 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NSD2 O96028 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
POLB P06746 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1736510 0.87 NOTUM (0.41) KMT2ANOTUMSMN1; SMN2MAPT
SCHEMBL1734637 0.84 MMP2 (0.49) MEN1KMT2AALDH1A1MMP2ANPEP
SCHEMBL1735684 0.84 CTSS (0.41) MEN1KMT2AALDH1A1RAB9AHSD17B10
SCHEMBL1735683 0.84 CTSS (0.41) MEN1KMT2AALDH1A1RAB9AHSD17B10
SCHEMBL1736744 0.83 GAA (0.40) MEN1KMT2AALDH1A1RAB9AHSD17B10
SCHEMBL1737333 0.78 ACACB (0.38) ALDH1A1RAB9AHSD17B10SMN1; SMN2POLB
SCHEMBL1735657 0.74 MAPT (0.44) MEN1KMT2AALDH1A1HSD17B10SMN1; SMN2
SCHEMBL1734754 0.71 MCL1 (0.44) MEN1KMT2AALDH1A1RAB9AMMP2
SCHEMBL1734756 0.71 MCL1 (0.44) MEN1KMT2AALDH1A1RAB9AMMP2
SCHEMBL1736975 0.70 FAAH (0.44) MEN1KMT2ACTSSNOTUML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 WO disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 US disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 MEN1 2714/4885KMT2A 2144/4885ALDH1A1 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.